Helix BioMedix and Levlad Announce Peptide License Agreement for Use in New Acne Treatment System |
Levlad's Nature's Gate(R) Organics Natural Results(TM) Acne Treatment System
with Oligopeptide-10 is being Launched Today at Natural Products Expo East
BOTHELL, Wash., Sept. 15 /PRNewswire-FirstCall/ -- Helix BioMedix, Inc.
(Bulletin Board: HXBM), a leading developer of proprietary bioactive peptides,
and Levlad Inc., a leading manufacturer and marketer of branded natural and
organic personal care products, today announced that the companies have
entered into a definitive license agreement for Helix BioMedix's proprietary
HB64 peptide, being marketed as Oligopeptide-10. Oligopeptide-10 is a key
ingredient in Levlad's Nature's Gate(R) Organics Natural Results(TM) Acne
Treatment System, which is being introduced at Natural Products Expo East, a
showcase of the latest trends in the natural and organic industry currently
taking place in Washington, D.C. The Natural Results(TM) Acne Treatment
System is expected to be available for sale Fall 2005.
"Anti-acne products sold over the counter represent a $350 million U.S.
market, yet studies show that consumers remain unsatisfied with their
performance," stated R. Stephen Beatty, President and CEO of Helix BioMedix.
"In a 27 person panel test, HB64 demonstrated 96% consumer acceptance and
independent studies showed user benefits after just a few days of use. We are
excited that Levlad has chosen to incorporate our proprietary peptide
technology as a key feature of their new anti-acne product. The license is
another example of the strength of our technology and further demonstrates our
ability to move beyond the development stage."
"Oligopeptide-10, combined with Salicylic Acid, is clearly the new
'superpower' in acne control," Levlad's President, Paddy Spence, commented.
"The combination of this remarkable technology with the other natural
ingredients in our new acne care system offers the consumer a powerful and
exciting option for controlling acne gently and effectively."
Natural Results(TM) Acne Treatment System is a revolutionary,
dermatologist-tested, acne treatment system for use at home. It is the first
acne treatment system of its kind to contain Oligopeptide-10, one of the
latest scientific breakthroughs in acne management. This unique fusion of 15
naturally occurring amino acids is combined with Salicylic Acid to form a
powerful duo that works synergistically to eliminate bacteria and combat
blemishes. The added benefit of encapsulated Tea Tree Leaf Oil is
particularly beneficial to acne-prone skin and helps to reduce redness for a
clear improvement in the skin's overall condition.
About Levlad
Levlad, Inc., with headquarters in Chatsworth, California, is a leading
manufacturer and marketer of branded natural and organic personal care
products, including shampoos, conditioners, soaps, skin care, bath gels,
lotions, deodorants and toothpaste, under the brand names Nature's Gate(R),
Nature's Gate(R) Organics(R), and Nature's Gate Organic Therapy which are sold
through specialty retailers nationwide. Levlad's branded products utilize
all-natural herbs and pH-balanced formulas, and reflect the company's ongoing
commitment to environmentally friendly and cruelty-free production. Levlad
also provides value-added turnkey manufacturing and formulation services to
private label customers, including a number of fast-growing consumer products
marketers and retailers. Levlad was acquired by Harvest Partners, a leading
New York-based private equity investment firm, in November 2004. Together
with its sister company Arbonne International, Inc., they comprise Harvest's
Natural Products Group, LLC holding company. Additional information on Levlad
and Nature's Gate can be found at http://www.levlad.com or at http://www.natures-gate.com
About Helix BioMedix
Helix BioMedix, Inc. is a late-stage biotechnology company that has a
portfolio of issued patents that covers six distinct classes of peptides,
covering over 1 million unique peptide sequences. The company's mission is to
become the industry leader in developing and commercializing small proteins
known as bioactive peptides. The antimicrobial and wound healing properties of
these peptides qualify them for inclusion in a wide range of both
pharmaceutical and consumer products. The company is currently focused on the
development of selected peptides as topical anti-infectives and in wound
healing. Non-pharmaceutical applications being pursued by Helix BioMedix
include adjuvants for cosmetics/cosmeceuticals, personal care, plant health,
animal health and wide-spectrum biocides. More information about the company
and its proprietary peptides can be found on the company's website at
http://www.helixbiomedix.com.
Important Notice
This press release contains forward-looking statements (statements which
are not historical facts) related to Helix BioMedix within the meaning of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements involve risks and uncertainties, including activities, events or
developments that the company expects, believes or anticipates will or may
occur in the future. A number of factors could cause actual results to differ
from those indicated in the forward-looking statements, including the
licensee's ability to successfully formulate and manufacture the Acne
Treatment System. Additional assumptions, risks and uncertainties are
described in detail in our reports and other filings with the Securities and
Exchange Commission. Such filings are available on our website or at
http://www.sec.gov. Readers are cautioned that such statements are not guarantees of
future performance and that actual results or developments may differ
materially from those set forth in the forward-looking statements. The company
undertakes no obligation to publicly update or revise forward-looking
statements to reflect subsequent events or circumstances.
Contact:
Helix BioMedix, Inc.
David Kirske, 425-402-8400
dkirske@helixbiomedix.com
Investor Relations:
Cameron Associates
Paul Henning, 212-554-5462 or paul@cameronassoc.com
SOURCE Helix BioMedix, Inc.
back to topRelated links:
CONTACT:
David Kirske of Helix BioMedix, Inc.,
+1-425-402-8400 or dkirske@helixbiomedix.com; or Investor
Relations: Paul Henning of Cameron Associates, +1-212-554-5462 or
paul@cameronassoc.com, for Helix BioMedix, Inc.
